2018 - The Year of the BioTechs, page-640

Is management to blame for someone selling $24,900 worth of shares?

We all know the share price is (and has been) a dog for many years; but based on yesterday’s presentation I believe the strategy is sound and the business fundamentals are strong.

- Quarter on Quarter revenue growth
- Scaling up for high end global distribution
- Significant gross margins on OTC products
- Growing best and first in class product range
- Midkine becoming increasingly derisked
- Midkine partnering potential becoming attractive

Sure, i would love the price to be higher but it is what it is.

I note on Maria’s Instagram feed she is in Melbourne; maybe presenting to potential investors?